Free Trial
NASDAQ:RAPP

Rapport Therapeutics Q1 2025 Earnings Report

Rapport Therapeutics logo
$10.92 -0.11 (-1.00%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$10.90 -0.02 (-0.18%)
As of 06/20/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rapport Therapeutics EPS Results

Actual EPS
-$0.68
Consensus EPS
-$0.77
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Rapport Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rapport Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Rapport Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Rapport Therapeutics Earnings Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Rapport Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rapport Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rapport Therapeutics and other key companies, straight to your email.

About Rapport Therapeutics

Rapport Therapeutics (NASDAQ:RAPP) Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

View Rapport Therapeutics Profile

More Earnings Resources from MarketBeat